

|  |  |
| --- | --- |
| **Examination question paper:** | **July 2024** |

|  |  |
| --- | --- |
| **Module code:**  **Component number:** | **BM7048**  **002** |
| **Module title:** | **Cancer Immunotherapy** |
| **Module leader:** | **Prof. Jameel M. Inal** |

|  |  |
| --- | --- |
| **Date:** | **July 2024** |
| **Duration:** | **1 Hour 30 Minutes** |

|  |  |
| --- | --- |
| **Exam type:** | **Seen, Closed** |
| **Materials supplied:** | **None** |
| **Materials permitted:** | **None** |
| **Warning:** | **Candidates are warned that possession of unauthorised materials in an examination is a serious assessment offence.** |

|  |  |
| --- | --- |
| **Instructions to candidates:** | **Answer all THREE questions** |
|  |  |
|  |  |
|  | **Do not turn page over until instructed** |

© London Metropolitan University

Answer all THREE questions

Q1. With reference to the tumour microenvironment and cancer metastasis, discuss recent findings, particularly noting David Lyden’s seminal work, on how exosomes derived from primary tumours may set up a pre-metastatic niche.

20 marks

Q2. Critically assess the role of dexosomes (dendritic cell-derived exosomes) as cancer vaccines.

20 marks

Q3. In relation to antigen-specific T cell therapy explain in detail some of the problems that engineered T cells encounter in the immunosuppressive tumour microenvironment.

20 marks